Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences, Tokyo 192-0392, Japan.
Division of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8555, Japan.
Int J Mol Sci. 2019 May 4;20(9):2195. doi: 10.3390/ijms20092195.
Legumain, a recently discovered cysteine protease, is increased in both carotid plaques and plasma of patients with carotid atherosclerosis. Legumain increases the migration of human monocytes and human umbilical vein endothelial cells (HUVECs). However, the causal relationship between legumain and atherosclerosis formation is not clear. We assessed the expression of legumain in aortic atheromatous plaques and after wire-injury-induced femoral artery neointimal thickening and investigated the effect of chronic legumain infusion on atherogenesis in mice. We also investigated the associated cellular and molecular mechanisms in vitro, by assessing the effects of legumain on inflammatory responses in HUVECs and THP-1 monocyte-derived macrophages; macrophage foam cell formation; and migration, proliferation, and extracellular matrix protein expression in human aortic smooth muscle cells (HASMCs). Legumain was expressed at high levels in atheromatous plaques and wire injury-induced neointimal lesions in mice. Legumain was also expressed abundantly in THP-1 monocytes, THP-1 monocyte-derived macrophages, HASMCs, and HUVECs. Legumain suppressed lipopolysaccharide-induced mRNA expression of vascular cell adhesion molecule-1 (), but potentiated the expression of interleukin-6 () and E-selectin () in HUVECs. Legumain enhanced the inflammatory M1 phenotype and oxidized low-density lipoprotein-induced foam cell formation in macrophages. Legumain did not alter the proliferation or apoptosis of HASMCs, but it increased their migration. Moreover, legumain increased the expression of collagen-3, fibronectin, and elastin, but not collagen-1, in HASMCs. Chronic infusion of legumain into mice potentiated the development of atherosclerotic lesions, accompanied by vascular remodeling, an increase in the number of macrophages and ASMCs, and increased collagen-3 expression in plaques. Our study provides the first evidence that legumain contributes to the induction of atherosclerotic vascular remodeling.
组织蛋白酶 L,一种新发现的半胱氨酸蛋白酶,在颈动脉粥样硬化患者的颈动脉斑块和血浆中均增加。组织蛋白酶 L 增加人单核细胞和人脐静脉内皮细胞(HUVEC)的迁移。然而,组织蛋白酶 L 与动脉粥样硬化形成之间的因果关系尚不清楚。我们评估了组织蛋白酶 L 在主动脉粥样硬化斑块中的表达,并研究了在 wire-injury 诱导的股动脉新生内膜增厚后组织蛋白酶 L 的表达,以及慢性组织蛋白酶 L 输注对小鼠动脉粥样硬化形成的影响。我们还通过评估组织蛋白酶 L 对 HUVEC 中炎症反应的影响,THP-1 单核细胞衍生的巨噬细胞;巨噬细胞泡沫细胞形成;以及人主动脉平滑肌细胞(HASMCs)的迁移、增殖和细胞外基质蛋白表达,在体外研究了相关的细胞和分子机制。组织蛋白酶 L 在小鼠的粥样斑块和 wire injury 诱导的新生内膜损伤中高表达。组织蛋白酶 L 在 THP-1 单核细胞、THP-1 单核细胞衍生的巨噬细胞、HASMCs 和 HUVECs 中也大量表达。组织蛋白酶 L 抑制脂多糖诱导的血管细胞黏附分子-1()的 mRNA 表达,但增强 HUVECs 中白细胞介素-6()和 E-选择素()的表达。组织蛋白酶 L 增强了巨噬细胞的炎症 M1 表型和氧化型低密度脂蛋白诱导的泡沫细胞形成。组织蛋白酶 L 不会改变 HASMCs 的增殖或凋亡,但会增加它们的迁移。此外,组织蛋白酶 L 增加了 HASMCs 中胶原-3、纤维连接蛋白和弹性蛋白的表达,但不增加胶原-1 的表达。慢性输注组织蛋白酶 L 可增强载脂蛋白 E 缺陷小鼠动脉粥样硬化病变的发展,同时伴有血管重塑、巨噬细胞和 ASMCs 数量增加以及斑块中胶原-3 表达增加。我们的研究首次提供了证据表明组织蛋白酶 L 有助于诱导动脉粥样硬化血管重塑。